Delving into the Latest Updates on VUmc with Synapse

Overview

Tags

Neoplasms

Infectious Diseases

Congenital Disorders

DNA vaccine

Radiopharmaceuticals and diagnostic agent

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Infectious Diseases	2
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

DNA vaccine	2
Therapeutic vaccine	1
Synthetic peptide	1
Prophylactic vaccine	1
Radiopharmaceuticals and diagnostic agent	1

Top 5 Target	Count

HPV E7	1
IL-17(Interleukin-17)	1
HPV E6	1
CD1d x TCRDV2	1

The goal of this clinical trial is to compare brief-intensive cognitive-behaviour therapy (CBT) with regular weekly CBT in people with anxiety-related disorders.
The main question to answer is: will brief-intensive CBT improve functioning (work, family, social) more and faster than does regular weekly CBT?
Participants will be asked to follow CBT treatment (20 sessions of 45 minutes in both conditions), and participate in 7 measurements with a total duration of 5 hours over 1 year.
Researchers will compare:
Brief-intensive CBT: 16 sessions in 2 weeks + 4 follow-up sessions within 3 months
Regular CBT with 20 weekly sessions in 6 months

Start Date01 Dec 2023

Sponsor / Collaborator

VUmc

NL-OMON25971

/ SuspendedNot ApplicableIIT

Exploring the effects of Street Temptations on cognitive distortions and treatment motivation within behaviorally at-risk adolescents

Start Date01 Sep 2021

Sponsor / Collaborator

VUmc

NL-OMON21916

/ RecruitingNot ApplicableIIT

Longitudinal prediction of progression in MS: 'The Amsterdam MS Cohort'

Start Date25 May 2021

Sponsor / Collaborator

VUmc

100 Clinical Results associated with VUmc

Login to view more data

0 Patents (Medical) associated with VUmc

Login to view more data

19,747

Literatures (Medical) associated with VUmc

01 Feb 2025·Life Sciences

Retraction notice to “Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways” [Life Sci. 249 (2020) 117470]

Author: Rahmani, Farzad ; Khazaei, Majid ; Ryzhikov, Mikhail ; Hassanian, Seyed Mahdi ; Asgharzadeh, Fereshteh ; Ferns, Gordon A ; Giovannetti, Elisa ; Barneh, Farnaz ; Avan, Amir ; Parizadeha, Mohammad Reza ; Jafari, Mohieddin ; Ahmadian, Mohammad Reza

01 Feb 2025·European Journal of Cancer

Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056]

Author: Aarts, M J B ; van den Berkmortel, F W P J ; de Groot, J W B ; Bonenkamp, J J ; Bloem, M ; Vreugdenhil, G ; van den Eertwegh, A J M ; Blank, C U ; Stevense-den Boer, A M ; Holtslag, C E ; Portielje, J E A ; Boers-Sonderen, M J ; van den Bos, F ; de Glas, N A ; Özkan, A ; van der Veldt, A A M ; Wouters, M W J M ; Kapiteijn, E ; Haanen, J B ; Suijkerbuijk, K P M ; van Rijn, R S ; Piersma, D ; Blokx, W A M ; Hospers, G A P

15 Jan 2025·The Journal of Maternal-Fetal & Neonatal MedicineQ4 · MEDICINE

Reproductive outcomes in women with mild intrauterine adhesions; a systematic review and meta-analysis

Q4 · MEDICINE

Review

Author: Hooker, Angelo B. ; Mansvelder, Floor J. ; Elbers, Roy G. ; Frijmersum, Zayel

BACKGROUNDModerate to severe intrauterine adhesions (IUAs) may greatly impact fertility, predisposing to pregnancy and obstetric complications. The impact of mild IUAs on reproductive performance remains unclear. A systematic review and meta-analysis was performed to examine the long-term reproductive outcomes in women with hysteroscopic identified and treated mild IUAs mild intrauterine adhesions (IUAs).METHODSAn electronic literature search was conducted using MEDLINE and EMBASE from inception to June 2019. All prospective cohort, cross-sectional studies or randomized controlled trials Clinical trials in which reproductive outcomes of women with mild IUAs, were reported were included.RESULTSFive studies, reporting on reproductive outcomes of 229 women with hysteroscopic identified and treated mild IUAs, were included. The pregnancy rate was 62.3% (142 of 228; 95% CI: 0.55-0.72, I² 25%, p = .21) and in 86.6% (123 of 142) a live birth was encountered (95% CI: 0.71-0.97) with 83.1% (108 out of 130) term deliveries (95% CI: 0.53-0.95). A miscarriage was reported in 10% (13 of 130; 95% CI: 0.02-0.26). Due to the lack of a control group, reproductive outcomes were compared to a general population. Pregnancy and live birth rates were significantly lower in women with identified and treated mild IUAs, 90% versus 62.3% and respectively 99.5% versus 86.6%. The miscarriage rate was similar. Data on obstetric and neonatal outcomes are lacking.CONCLUSIONSWomen with hysteroscopic identified and treated mild IUAs seem to have lower pregnancy and live birth rate compared to the general population. Future studies consisting of a large cohort of women with hysteroscopic identified and treated IUAs with structural follow-up and a control group are needed to confirm our findings.

100 Deals associated with VUmc

Login to view more data

100 Translational Medicine associated with VUmc

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 2 Clinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TTFC-E7SH ( HPV E7 )	HPV16 Infection More	Phase 2 Clinical
LAVA-051 ( CD1d x TCRDV2 )	Chronic Lymphocytic Leukemia More	Preclinical
[18F]FLUORIDE PET-CT	Ankylosing Spondylitis More	Preclinical
Alanylglutamine ( IL-17 )	Peritoneal Fibrosis More	Preclinical
TTFC-E6SH ( HPV E6 )	HPV-related carcinoma More	Preclinical